supplementary materials: Gentamicin sponge for anti-infection, a controversial old topic and preliminary exploration of the solution, in vitro and in vivo experiments. abstract: Although gentamicin sponge is approved for preventing or treating surgical infection in many countries, the effectiveness of it has still been controversial. Our study was to construct drug-loading and drug-release quantitative equation of gentamicin sponge, in addition, obtain the wound infection prevented and treated scheme of gentamicin sponge. Firstly, sponge was cut into 1×1×0.5cm size and immersed into 40mg/ml, 16mg/ml, 8mg/ml, 4mg/ml, 1.6mg/ml, 0.8mg/ml or 0mg/ml gentamicin solution to evaluate gentamicin-loading of sponge. Secondly, different air-dried gentamicin-saturated sponge was immersed into 10ml 0.9% physiological saline to analyze the drug-release of gentamicin sponge. Thirdly, methicillin sensitive Staphylococcus aureus (MSSA) and Pseudomonas aeruginosa (P. aeruginosa) were used to explore the infection prevented scheme of gentamicin sponge. Finally, femur fractured with wound infection rat model was used to discuss the infection treated scheme. Then, the equation of gentamicin-loading of sponge was: z=(0.03718±0.01672)x+(-4.578e-4±0.06253)y+(-2.50935e-4±1.47521e-4)x2+(0.00303±0.00149)y2+(0.00408±3.52827e-4)xy (R2 was 0.97) and drug-release equation was z=(4.37205±1.18048)x+(-7.05921±3.09628)y+(-0.04596±0.01287)x2+(0.3309±0.07912)y2+(0.31559±0.02754)xy (R2 was 0.95). 1.6 mg/ml air-dried sponge and 0.8mg/ml air-dried sponge were enough to prevent wound infection. Besides, if wound were confirmed to be sensitive bacteria infected, we recommended to use 40mg/ml air-dried sponge, 16mg/ml air-dried sponge or 8mg/ml air-dried sponge to treat.
Contributors:Tatiana V. Raudina, Sergey Loiko, D.M. Kuzmina, L.S. Shirokova, Sergey Kulizhskiy et al
The full data set of measured DOC, major and trace element concentrations in the 4 main fractions of peat porewaters (< 0.45 µm, < 100 kDa, < 30 kDa and < 3 kDa) in all sites, micro-landscapes and different sampling depths is presented.
ST1: Abbreviations: mo, months; HTN, hypertension; C, Caucasian; LE, lower extremity; UE, upper extremity; CR, complete remission; PR, partial response; AWD, alive with disease; DOD, died of disease; IFN, Interferon-α-2a; Bex, bexarotene; Gem, gemcitabine; PUVA, psoralen (P) and ultraviolet A (UVA); NB-UVB, narrow band-ultraviolet B; BMT, bone marrow transplant. TNMB classifications and disease stages were based on the 2007 staging guidelines defined by the International Society of Cutaneous Lymphomas and the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Task Force.
ST2: lymphoid cells as positive if > 50% of cells showed staining, focally positive if 10-50% (+/-) of cells showed staining, and negative if 50% of cells were positive, and partial/subtotal loss of expression if <50% (+/-) of cells were positive. Molecular pathology results of T-cell receptor (TCR) gene rearrangement, including TCRγ and TCR𝛽 were a part of the routine workup and were retrieved from the medical records. The first row of Case 4 refers to the plaques and the second row to the tumours. EBER, EBV-encoded RNA; GB, granzyme B; TIA-1, T-cell intracellular antigen-1; TCR, T-cell receptor.
SF1: A-B) Case 1 presenting with a ~ 5 cm confluent reddish-brown annular patch with overlying scale on the right lower abdomen and right flank. C-F) Case 2 initial cutaneous lesions exhibiting variable sized reddish brown annular patches and plaques with overlying scale to the trunk and left axillary region. F) Case 2 demonstrating stage progression with a dark red multi-lobed tumours with overlying scale involving the right nasal sidewall. G-H) Case 3 initially demonstrating erythematous scaly patches and plaques symmetrically on the trunk and proximal lower extremities and. I-J) Case 4 initially manifesting erythematous scaly patches and plaques on the trunk and upper extremities (E), and subsequently developing ulcerating tumours on the right plantar
SF2: A) H&E reveals an atypical lymphoid infiltrate within the epidermis and reactive superficial dermal infiltrate. The epidermotropic lymphoma cells are small-to-medium size with perinuclear halos and hyperchromatic nuclei. Intraepidermal T-cells are negative for CD4 (B), CD8 (C), and Beta-F1 (D). Reactive superficial dermal infiltrate stains positive for Beta-F1 and CD4. Epidermotropic lymphoid cells strongly express TCR-δ (E) and cytotoxic marker TIA (F). G) H&E, atypical lymphoid infiltrate indistinguishable from that or early-stage MF and 2019 biopsy. A reactive superficial dermal infiltrate is noted. H) Epidermotropic lymphoid cells are positive for T-cell marker, CD3, show scant CD4 expression (I) and negative CD8 expression (J).
Contributors:Mitchell Hunter, Armen Kemanian, David Mortensen
Briefly, this dataset includes ecophysiological and yield measurements from a two-site-year study of maize grown following five functionally diverse cover crop treatments under imposed drought conditions. The experiment is described in detail in the following publications:
- Hunter, M., A. Kemanian, D. Mortensen. In review. Cover Crops and Drought: Maize Ecophysiology and Yield Dataset. Data in Brief.
- Hunter, M., A. Kemanian, D. Mortensen. In review. Cover crop effects on maize drought stress and yield. Agriculture, Ecosystems, and the Environment.
- Hunter M. 2018. Sustainable intensification and climate resilience: Cover crops, soil improvement, and drought. Ph.D. dissertation, The Pennsylvania State University.